文献速递流行病学与生物统计临床试验与 GCP

社区结核病主动病例发现两种诊断干预包比较:一项开放标签随机对照试验

Comparison of two diagnostic intervention packages for community-based active case finding for tuberculosis: an open-label randomized controlled trial.
PubMed 文献 · Nat Med · 2023-03-09

在南非开普敦城郊非正式定居点开展开放标签随机对照试验,对584名HIV感染者或结核症状者1:1随机分组,比较当日涂片镜检与现场DNA分子诊断(GeneXpert)至治疗启动时间。Xpert组启动治疗显著更早(8天 vs 41天,P=0.002),但仅检出52%培养阳性结核;Xpert检出几乎所有可能传染性患者(94.1% vs 23.5%,P<0.001)。

要点

  • Xpert组至治疗启动中位时间8天,涂片镜检组41天(P=0.002)。
  • Xpert仅检出52%培养阳性结核,但检出94.1%可能传染性患者,涂片镜检为23.5%(P<0.001)。
  • 60天时Xpert阳性者治疗比例100%,全部培养阳性者为46.5%(P<0.01)。

核心结论

  • 研究结果挑战被动病例发现的公共卫生策略传统范式,主张将便携式DNA诊断与照护链接作为面向社区的传播阻断策略实施。

研究设计与样本

  • 开放标签随机对照试验,在南非开普敦城郊非正式定居点通过社区移动诊所对5274人进行结核症状筛查。
  • 584名HIV感染者或结核症状者接受靶向诊断筛查并1:1随机分为当日涂片镜检组(n=296)或现场DNA分子诊断组(n=288;GeneXpert)。
  • 主要目标为比较两组至结核治疗启动时间,次要目标包括可行性和可能传染性患者的检出。

主要发现

  • 靶向筛查参与者中9.9%(58/584)为培养确诊结核。
  • Xpert组至治疗启动显著早于涂片镜检组(8天 vs 41天,P=0.002)。
  • Xpert仅检出52%的培养阳性结核患者。
  • Xpert检出94.1%的可能传染性患者,涂片镜检检出23.5%(P<0.001)。
  • Xpert组可能传染性患者至治疗中位时间更短(7天 vs 24天,P=0.02),60天时可能传染性患者治疗比例高于可能非传染性患者(76.5% vs 38.2%,P<0.01);60天时Xpert阳性参与者治疗比例高于全部培养阳性参与者(100% vs 46.5%,P<0.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Two in every five patients with active tuberculosis (TB) remain undiagnosed or unreported. Therefore community-based, active case-finding strategies require urgent implementation. However, whether point-of-care (POC), portable battery-operated, molecular diagnostic tools deployed at a community level, compared with conventionally used POC smear microscopy, can shorten time-to-treatment initiation, thus potentially curtailing transmission, remains unclear. To clarify this issue, we performed an open-label, randomized controlled trial in periurban informal settlements of Cape Town, South Africa, where we TB symptom screened 5,274 individuals using a community-based scalable mobile clinic. Some 584 individuals with HIV infection or symptoms of TB underwent targeted diagnostic screening and were randomized (1:1) to same-day smear microscopy (n = 296) or on-site DNA-based molecular diagnosis (n = 288; GeneXpert). The primary aim was to compare time to TB treatment initiation between the arms. Secondary aims included feasibility and detection of probably infectious people. Of participants who underwent targeted screening, 9.9% (58 of 584) had culture-confirmed TB. Time-to-treatment initiation occurred significantly earlier in the Xpert versus the smear-microscopy arm (8 versus 41 d, P = 0.002). However, overall, Xpert detected only 52% of individuals with culture-positive TB. Notably, Xpert detected almost all of the probably infectious patients compared with smear microscopy (94.1% versus 23.5%, P = <0.001). Xpert was associated with a shorter median time to treatment of probably infectious patients (7 versus 24 d, P = 0.02) and a greater proportion of infectious patients were on treatment at 60 d compared with the probably noninfectious patients (76.5% versus 38.2%, P < 0.01). Overall, a greater proportion of POC Xpert-positive participants were on treatment at 60 d compared with all culture-positive participants (100% versus 46.5%, P < 0.01). These findings challenge the traditional paradigm of a passive case-finding, public health strategy and argues for the implementation of portable DNA-based diagnosis with linkage to care as a community-oriented, transmission-interruption strategy. The study was registered with the South African National Clinical Trials Registry (application ID 4367; DOH-27-0317-5367) and ClinicalTrials.gov (NCT03168945).

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Esmail A, Randall P, Oelofse S, et al. Comparison of two diagnostic intervention packages for community-based active case finding for tuberculosis: an open-label randomized controlled trial. Nat Med. 2023. PMID: 36894651. doi:10.1038/s41591-023-02247-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。